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framework. Under the classical approach, there is no probability associated with a parameter, and the
meaning of confidence intervals can be misconstrued by inexperienced students. With Bayesian
statistics, one can find the posterior probability distribution of an unknown parameter, and state the
probability of vaccine efficacy rate, which makes the communication of uncertainty more flexible. We use
a hypothetical example and a real baseball example to guide readers to learn the beta-binomial model
before analyzing the clinical trial data. This note is designed to be accessible for lower-level college
students with elementary statistics and elementary algebra skills.
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Introduction
On November 18, 2020, the drug maker Pfizer issued a press release summarizing
its Phase 3 study of COVID-19 vaccine (Pfizer 2020b). The announcement
received a flurry of media coverage (LaFraniere et al. 2020; Zimmer 2020),
focusing on the 95% vaccine efficacy rate. Pfizer’s clinical trial involved 41,135
volunteers; there were 170 confirmed cases of COVID-19, with 162 observed in
the placebo group and 8 in the vaccine group. Based only on these numbers reported
in the New York Times (Zimmer 2020), I wrote a pedagogic note for Numeracy to
verify Pfizer’s claim of 95% vaccine efficacy rate and test its statistical significance
(Wang 2021). I also used the method that students learn in a standard elementary
statistics course to construct an approximate confidence interval of the efficacy rate,
[92.1%, 98.5%], which was not given in the press release and news articles.
Since the completion of the manuscript of Wang (2021) in early December
2020, three leading COVID-19 vaccine developers (Pfizer-BioNTech, Moderna,
and AstraZeneca-Oxford) published additional details about their clinical trials
(Polack et al. 2020; Ramasamy et al. 2020; Baden et al. 2021). The US Food and
Drug Administration (FDA) held meetings on December 10 and 17, 2020 to discuss
Emergency Use Authorization of COVID-19 vaccines by Pfizer-BioNTech and
Moderna. The FDA meeting videos and documents are open to the public, and a
wealth of information is now available (FDA 2020b; FDA 2020c). Using a betabinomial model, Pfizer provided a confidence interval of [90.3%, 97.6%] for the
vaccine efficacy rate, and using the Clopper and Pearson method the confidence
interval is [90.0%, 97.9%]. The two intervals are similar, and in reasonable
agreement with my simplified treatment based on a one-proportion z-test.
To emphasize the need for confidence intervals, I often use the following
example from Selvin (2004): in a particular state it was noted that more than half
the women in prison for murder had killed their husbands, and less than a fifth of
the men in prison for murder had killed their wives. Can we draw conclusions about
male and female spousal relations? No. If only four women were convicted for
murder and 660 men, the confidence interval associated with the women would be
extremely wide and convey little information about the population parameter.
The COVID-19 pandemic offers a realistic example to illustrate the importance
of confidence intervals. The AstraZeneca-Oxford vaccine was described to be
puzzling for scientists (Callaway 2020). Among people who received a lower dose
followed by a standard dose, the efficacy rate is 90%. However, for participants
who received two full doses, the efficacy rate is 62%. The results may appear to be
confusing, but once we know that the first trial involved only 33 COVID-19 cases,
3 in the vaccine group and 30 in the placebo group, we expect the confidence
interval to be wide. Table 1 shows the raw counts of the numbers of COVID-19
cases and participants in three drug makers’ clinical trials. Based on the company’s
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publication (Ramasamy et al. 2020), confidence interval for the initial trial is
[67.4%, 97.0%], which overlaps with that of the two-dose regimen, [41.0%,
75.7%]. There is no statistically significant difference between these two reported
AstraZeneca-Oxford vaccine efficacy rates, and speculation about what works
better seems premature.
Table 1
Raw Data from Three Drug Makers’ Publications
Pfizer all
Pfizer age ≥ 65 years
Moderna all
AstraZeneca I
AstraZeneca II
AstraZeneca combined

Vaccine group
No. cases/volunteers
8/17,411
1/3,848
11/13,934
3/1,367
27/4,440
30/5,807

Placebo group
No. cases/volunteers
162/17,511
19/3,880
185/13,883
30/1,374
71/4,455
101/5,829

There are numerous ways to calculate confidence intervals (Newcombe
1998). In addition to Pfizer’s methods mentioned above, Moderna employed a
“stratified Cox proportional hazard model” and AstraZeneca utilized the “Poisson
regression model with robust variance.” The technical details about these methods
can dazzle even statisticians. This note focuses on the Bayesian approach, which is
not typically covered in elementary statistics courses. Some statisticians and
scientists argue that the standard classical technique has undesirable features, and
a Bayesian method can be more attractive (Efron 1986; Cousins 1995). Kranz
(2020) analyzed the FDA meeting video and claimed that the Pfizer scientist used
the Bayesian credible interval to make the presentation more understandable for
advisory committee members who are not statisticians.1 In some situations the
frequentist and Bayesian confidence intervals are similar or even identical, and
many textbooks have actually unknowingly used the Bayesian interpretation for the
frequentist confidence intervals. For instance, the widely recommended Chicago
Guide to Writing about Numbers (Miller 2004) contains the following example:
Suppose our sample yields a mean math test score of 73.1 points with a standard error of
2.1 points. The 95% confidence interval is 73.1 ± (2 × 2.1), so we can be 95% sure that
the average test score for the population falls between 68.9 and 77.3 points.

While this kind of statement can be found in many standard elementary
textbooks, strictly speaking such an interpretation is not what Jerzy Neyman
envisioned when he first introduced the concept of confidence intervals (Neyman
1937). In the Appendix we will find the Clopper-Pearson confidence intervals and
interpret them the classical way.
We will use a simplified method based on Bayesian statistics to calculate
confidence intervals for data shown in Table 1 to allow students to better understand
1

The phrase credible interval was coined to distinguish it from the classical confidence interval. In
this note I use “confidence intervals” regardless of whether the construction is classical or Bayesian.
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and communicate COVID-19 vaccine clinical trials. We refrain from cluttered
notation commonly appearing in Bayesian literature, but keep the mathematics at
the level of elementary statistics and elementary algebra to make this note
accessible for most college students. We start with a discussion of the beta
probability distribution, related to the polynomial and power functions. We then
introduce Bayes’s rule and the beta-binomial model, and guide the readers to
understand the theory through examples. After the preparatory work, we apply the
method to analyze drug makers’ data to find the Bayesian confidence intervals.

The Beta Distribution
We first use the familiar normal distribution to recall probabilistic properties. A
normal distribution is characterized by two parameters, the mean and the standard
deviation. For the standard normal distribution, or the z-distribution, the mean is 0
and standard deviation is 1. The probability density function (pdf) is
𝑓(𝑧) =

1
√2 𝜋

𝑒 −𝑧

2 /2

.

The graph of this function is the famous bell curve, and the area under the curve
between two z scores represents the probability. The middle 95% of the area under
the z-distribution pdf is bounded by 𝑧 = −1.96 and 𝑧 = 1.96. In principle, the areas
need to be found by integration, but students and practitioners use a table (in the
old days) or a computer program to retrieve pre-calculated integral values for the
standard normal distribution.
The normal distribution is ubiquitous in an elementary statistics course and in
real applications, but it is not the only type of probability distribution. An important
class of distribution is the beta distribution, characterized by two parameters 𝛼 and
𝛽. We use the notation 𝑥~Beta(𝛼, 𝛽) to denote that the random variable X follows
a beta distribution. We use upper-case letters to refer to random variables, and
lower-case letters to refer to their actual observed values. The probability density
function is proportional to
𝑝(𝑥) ∝ 𝑥 𝛼−1 (1 − 𝑥)𝛽−1 ,

0≤ 𝑥 ≤ 1.

The pdf of Beta(1, 1) is simply 1, a constant function. The pdf for Beta(2, 2)
is
𝑝(𝑥) = 6𝑥(1 − 𝑥) ,
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whose graph is a familiar opening downward parabola that students should know
how to hand-sketch when learning elementary algebra. For other values of 𝛼 and
𝛽, students can use a graphing device to plot the curves. Consider Beta(3, 19), the
pdf is
𝑝(𝑥) = 𝑘𝑥 2 (1 − 𝑥)18 ,
where k is a proportionality constant to ensure that the area under the curve between
0 and 1 is unity, so that the area under the curve between two x values represents
the probability.2 The graph is shown in Figure 1. We will use this distribution to
model the hospitalization rate later.

Figure 1. Probability density function of Beta(3, 19), which is proportional to 𝑥 2 (1 − 𝑥)18 . The
vertical line indicates the mean 3/22 = 0.136, which is the horizontal coordinate of the centroid of
the shape.

The mean of a continuous random variable following a certain probability
distribution is the horizontal coordinate of the centroid of the area under the pdf. It
is an elementary calculus problem to find the area and centroid of a shape, but we
will not get into the details. For a Beta distribution, we cite the well-established
results for the mean and variance (Gelman et al. 2013):

2

The proportionality constant k can be expressed as the beta function which is coded in standard
mathematical and statistical software.
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E(𝑋) =

𝛼
,
𝛼+𝛽

var(𝑋) =

(𝛼 +

𝛽)2

𝛼𝛽
.
(𝛼 + 𝛽 + 1)

For example, for Beta(3, 19), the mean is 3/(3 + 19) = 0.136, which is
indicated by the vertical line in Figure 1.

Bayes’s Rule and the Beta-Binomial Model
Bayes’s rule can be simply stated as “the posterior is proportional to the likelihood
times the prior.” Formally,
𝑝(𝜃|𝑦) ∝ 𝑝(𝜃)𝑝(𝑦|𝜃) ,
where 𝑝(𝜃|𝑦) and 𝑝(𝜃) are the posterior and prior distributions of the parameter 𝜃,
respectively, and 𝑝(𝑦|𝜃) is the likelihood. The beta-binomial model uses the
binomial sampling model as the likelihood, which is
𝑝(𝑦|𝜃) = 𝐶𝑦𝑛 𝜃 𝑦 (1 − 𝜃)𝑛−𝑦 ,
where 𝐶𝑦𝑛 is the binomial coefficient; see Wang (2021) for a discussion or any
statistics textbooks for background information. For this likelihood, it is natural to
use a beta distribution as the prior. As a result, the binomial model with beta prior
distribution introduced in the preceding section has a posterior like this:
𝑝(𝜃|𝑦) ∝ 𝜃 𝑦+𝛼−1 (1 − 𝜃)𝑛−𝑦+𝛽−1 .
The posterior is also a beta distribution, 𝜃|𝑦 ~ Beta(𝛼 + 𝑦, 𝛽 + 𝑛 − 𝑦), and
the mean is
E(𝜃|𝑦) =

𝛼+𝑦
.
𝛼+𝛽+𝑛

The posterior mean invariably lies between the sample proportion 𝑦/𝑛 and the
prior mean 𝛼/(𝛼 + 𝛽) (Gelman et al. 2013). Before getting too abstract, we use
some examples from Connor (2021) published in Numeracy to illustrate the idea.

Hospitalization Rate
Suppose 2 out of 20 young students in a classroom need hospitalization after being
infected by COVID-19. Naively, we estimate the hospitalization rate for young
students to be 2/20 = 0.1, but if 2 out 20 senior citizens who live in an assisted
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living facility need hospitalization after being infected by COVID-19, it seems
unreasonable to conclude that the hospitalization rate for senior citizens is also
2/20 = 0.1, the same as students’ rate. The essence of Bayesian statistics is that
one needs to incorporate previously established research into the current one, by
including the previous knowledge as the prior distribution. If we use
Beta(200, 100) as the prior for people who live in an assisted living facility
(Connor 2021, Figure 3), then the posterior distribution is Beta(200 + 2, 100 +
18) and the Bayes-estimated hospitalization rate is
200 + 2
= 0.631.
200 + 100 + 20
On the other hand, if we use Beta(40, 4000) for students (Connor 2021, Figure
4), then the posterior distribution is Beta(40 + 2, 4000 + 18) and the Bayesestimate rate is
40 + 2
= 0.010.
40 + 4000 + 20
The hospitalization rate for people who live in an assisted living facility is
about 63 times higher than the rate for students using the Bayesian model, which
makes more sense. In further details, the likelihood for both groups is based on the
observation of 2 cases out of a sample of 20, and is modeled by this binomial
distribution,
𝑃(𝑦|𝜃) = 𝐶220 𝜃 2 (1 − 𝜃)18 ,
where 𝜃 is the unknown true rate. The prior Beta(200, 100) for people in an
assisted living facility has the following pdf:
𝑃(𝜃) = 𝑘𝜃199 (1 − 𝜃)99 ,
where k is a proportionality constant. This prior distribution can be viewed as the
following: previously 199 people with similar background required hospitalization,
and 99 did not. The posterior is proportional to the likelihood multiplied by the
prior,
𝑃(𝜃|𝑦) ∝ 𝜃199+2 (1 − 𝜃)99+18 ,
which is the pdf of the distribution Beta(200 + 2, 100 + 18). From this analysis,
the posterior mean 0.631 is just the weighted mean of the prior rate 200/(200 +
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100) = 0.667 and the sample proportion 2/20 = 0.1. Similarly, the prior pdf for
students is
𝑃(𝜃) = 𝑘𝜃 39 (1 − 𝜃)3999 ,
and the posterior pdf is:
𝑃(𝜃|𝑦) ∝ 𝜃 39+2 (1 − 𝜃)3999+18 .
A nice feature of the Bayesian method is that we obtain a posterior probability
density function for the true parameter 𝜃 as seen above, so that we can discuss the
probability of the parameter. In the next section we will see how a Pfizer scientist
used the distribution when communicating about the vaccine efficacy.
In Figure 2, we show the prior and posterior probability density functions for
two groups. We include the likelihood function in the same plot, but the likelihood
function is not a probability density function. Note that 𝑃(𝑦|𝜃) = 𝐶220 𝜃 2 (1 −
𝜃)18 is proportional to the pdf of Beta(3, 19). See also Figure 1. For people in an
assisted living facility, we can see that the posterior mean 0.631 is between the prior
mean 0.667 and the raw rate 0.1. This can be considered as the phenomenon
“regression to the mean.” For students in a classroom, we make a similar
observation that the posterior mean 0.010 is between the prior mean 40/(40 +
4000) = 0.0099 and the raw rate 0.1, although the data 2 out of 20 are dominated
by the prior distribution and we can hardly distinguish the prior and posterior
probability density functions from Figure 2.

Figure 2. The dot-dashed curve is the prior, dashed curve is proportional to the likelihood, and the
solid curve is the posterior, for people in an assisted living facility (left) and students in a classroom
(right). The dashed curve for both plots is the same function as the curve in Figure 1 but shown in
different scale.
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Baseball Batting Average
This real-life example is from Irizarry and Love (2015). José Iglesias is a
professional baseball player. In April 2013, he made 9 hits out of 20 times at
bat. The raw rate, called batting average, is 9/20 = 0.450. It is strikingly high,
as no one has finished a season with an average of 0.400 since Ted Williams did it
in 1941. Irizarry and Love calculated the batting averages for all players with more
than 500 at bats during the previous three seasons, and found the mean to be 0.275
and standard deviation 0.027. They used a normal distribution to compute the
posterior distribution, but here we will use the beta-binomial model. From the
records of the previous three seasons, we set the following equations to solve for 𝛼
and 𝛽,
𝛼
= 0.275 ,
𝛼+𝛽

(𝛼 +

𝛽)2

𝛼𝛽
= 0.0272 .
(𝛼 + 𝛽 + 1)

One can employ a computer algebra system such as Maple or Mathematica to
solve this system of two equations with two unknowns to obtain 𝛼 = 74.935 and
𝛽 = 197.556. With the prior distribution Beta(74.935, 197.556), the posterior
distribution is Beta(74.935 + 9, 197.556 + 11), and the Bayes-estimated rate for
Iglesias is
74.935 + 9
= 0.287.
74.935 + 197.556 + 20
The posterior distribution
𝑃(𝜃|𝑦) ∝ 𝜃 74.935−1+9 (1 − 𝜃)197.556−1+11
is shown in Figure 3, along with the prior and likelihood. The posterior pdf allows
us to construct a Bayesian 95% confidence interval, denoted by [𝐿, 𝑈]. The lower
bound is the value such that the area under the pdf between 0 and L is 0.025, and
the upper bound is the value such that the area under the pdf between U and 1 is
0.025. This is an elementary area problem that students learn in calculus, but many
computer programs exist to perform numerical integration and locate the end
points. Using the R command qbeta(c(0.025, 0.975), 74.935+9, 197.556+11), we
obtain the 95% confidence interval [0.237, 0.340]. We conclude that based on José
Iglesias’s performance in April 2013, there is a 95% probability that his true batting
average is between 0.237 and 0.340. We can talk about the probability of the
parameter (batting average), which we cannot do under the classical framework.

https://scholarcommons.usf.edu/numeracy/vol14/iss2/art7
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Figure 3. Left: The dot-dashed curve is the prior, dashed curve is proportional to the likelihood, and
the solid curve is the posterior. Right: The shaded area under the posterior pdf between the end
points of the 95% confidence interval, [0.237, 0.340], is 0.95.

The Bayes-estimated rate 0.287 turned out to be a more accurate prediction
than the raw rate 0.45. From May to September, Iglesias had 97 hits out of 330, or
a batting average of 0.293.3 The Bayesian prediction that he would not be as good
the remainder of the season is another example of regression to the mean.

Vaccine Efficacy Rates
According to the FDA issued guidance, the vaccine efficacy rate should be at least
50% to be considered a success, although the lower bound of the confidence
interval can be as low as 30% (FDA 2020a), another reminder that confidence
intervals are crucial. To ensure public trust, Pfizer, Moderna, and AstraZeneca
agreed to make their full study protocols publicly available. Pfizer used the FDA
recommendations to construct a minimally informative prior beta distribution for
the Bayesian confidence interval (Pfizer 2020a), as we will describe below.
From Pfizer’s protocol, we learn that the vaccine efficacy is defined as
VE = 1 − IRR ,
where IRR is the ratio of COVID-19 illness rate in the vaccine group to the illness
rate in the placebo group. The parameter 𝜃 is defined as
𝜃=

1 − VE
.
2 − VE

From the above definition, we can find a formula for VE in terms of 𝜃:
3

Reviewer 1 used a uniformly distributed prior (𝛼 = 1, 𝛽 = 1) to find the 95% confidence interval
[0.257, 0.660], which also encompasses the true batting average. The empirical approach using other
players’ data, however, provides a much more precise prediction.
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VE =

1 − 2𝜃
.
1−𝜃

In Wang (2021), I used the New York Times description to express the efficacy
rate as follows:
VE = 1 −

𝑃(COVID+|vaccine)
,
𝑃(COVID+|placebo)

where 𝑃(COVID+|vaccine) and 𝑃(COVID+|placebo) are the number of cases in
vaccine and placebo groups, respectively. Pfizer’s illness rate is measured in units
of per 1000 person-years. Because we lack detailed temporal information of the
clinical trial results, we make an approximation of equal surveillance time for the
vaccine and control groups to simplify the calculation. With such an approximation
and some algebraic operations, we obtain
𝜃=

𝑃(COVID+|vaccine)
.
𝑃(COVID+|vaccine) + 𝑃(COVID+|placebo)

The November 18, 2020 press release from Pfizer (Pfizer 2020b) and the New
York Times article (Zimmer 2020) did not provide the number of volunteers in each
group, so I resorted to Bayes’s rule to relate the inverse probabilities:
𝑃(vaccine|COVID+) 𝑃(vaccine) 𝑃(COVID+|vaccine)
=
×
.
𝑃(placebo|COVID+) 𝑃(placebo) 𝑃(COVID+|placebo)
See Wang (2021) for further discussion. With the approximation
𝑃(vaccine) = 𝑃(placebo),4 we can express 𝜃 as
𝜃=

𝑃(vaccine|COVID+)
.
𝑃(vaccine|COVID+) + 𝑃(placebo|COVID+)

This definition allows us to estimate the raw rate for Pfizer to be 𝜃 = 8/170,
based on the observed 8 people in the vaccine group among 170 COVID-positive
volunteers. We also have the vaccine efficacy rate as follows:

4

To analyze the clinical trial of the Sputnik V vaccine in Russia, which involved 14,964 volunteers
in the vaccine group and 4,902 people in the placebo group (Logunov et al. 2021), we have
developed a more general formulism and will present it in a future publication.
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VE =

8
1 − 2 × 170
8
1 − 170

=

154
8
= 1−
= 0.951.
162
162

I show extra steps in arithmetic so that the reader can relate to my earlier treatment
(Wang 2021).
To find the Bayesian confidence interval, Pfizer constructed a minimally
informative prior. An uninformative prior is a constant function, or Beta(1, 1).
According to Pfizer’s protocol (Pfizer 2020a), they set the prior VE to have a mean
of 30%, the minimal requirement from the FDA guidance, and at this rate 𝜃 = (1 −
3/10)/(2 − 3/10) = 7/17 = 0.4118. Recall that for a beta distribution, the mean
is 𝛼/(𝛼 + 𝛽). Let us keep 𝛽 = 1, and we can solve for 𝛼:
𝛼
7
=
,
𝛼 + 1 17

𝛼=

7
.
10

This formula is the basis for Pfizer’s prior, Beta(0.700102, 1). The extra digits in
Pfizer 𝛼 is due to rounding error and seems superfluous.
We use the binomial sampling model for the likelihood. From the observed 8
cases in the vaccine group and 162 cases in the placebo group,
𝑃(𝑦|𝜃) = 𝐶8170 𝜃 8 (1 − 𝜃)162 .
The pdf for Beta(7/10, 1) is
𝑃(𝜃) = 𝑘𝜃 7/10−1 (1 − 𝜃)1−1 = 𝑘𝜃 −3/10 ,
where k is a proportional constant. The posterior pdf is
𝑃(𝜃|𝑦) ∝ 𝜃 7/10−1+8 (1 − 𝜃)162 ,
which is the pdf of Beta(7/10 + 8, 1 + 162). See Figure 4 for the prior and
posterior probability density functions, together with the likelihood. The Bayesestimated rate is

𝜃=

7
10 + 8

7
10 + 1 + 170
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VE =

1 − 2 × 0.0501
= 0.947.
1 − 0.0501
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Figure 4. Left: The dot-dashed curve is the prior, dashed curve is proportional to the likelihood, and
the solid curve is the posterior. Right: The shaded area under the posterior pdf of VE between the
end points of the 95% confidence interval, [0.903, 0.976], is 0.95.

Because the prior is minimally informative, the posterior rate is not too
different from the raw rate. Unlike examples in the preceding section, here the data
dominate the prior distribution. From the posterior distribution, we can use the R
command qbeta(c(0.025, 0.975), 7/10+8, 1+162) to solve the area problem to find
the 95% confidence interval for 𝜃 to be [0.0232, 0.0880], and the corresponding
VE confidence interval [90.3%, 97.6%]. This is identical to the confidence interval
in the briefing document that Pfizer submitted to the FDA for the December 10,
2020 meeting. Pfizer scientist Dr. William Gruber said the following during the
Advisory Committee meeting (FDA 2020b).
There’s 95 percent probability that efficacy falls in the intervals shown; meaning, that over
97.5 percent likelihood that the efficacy is greater than 90 percent. Likewise, the
probability that vaccine efficacy is at least greater than 30 percent greatly exceeds FDA
COVID-19 vaccine guidance.

Dr. Gruber’s testimony is an example that one can talk about the probability of the
true parameter, in this case vaccine efficacy rate, under the Bayesian framework.
From Pfizer’s document, we find that the 65-and-older subgroup has one case
in the vaccine group and 19 in the placebo group (see Table 1). We expect a wider
confidence interval for this age group. Similar to the above procedure, the posterior
distribution is Beta(7/10 + 1, 1 + 19). Below, we show how to use R to find the
95% confidence interval for 𝜃, [0.00765, 0.219], and the corresponding end points
of the confidence interval for VE, [71.9%, 99.2%].5 We can say that there is a 95%
probability that the vaccine efficacy rate is between 71.9% and 99.2% for people
of age 65 and over, based on the data.

5

Reviewer 2 noticed that the Bayesian confidence interval [71.9%, 99.2%] is slightly different from
the Clopper-Pearson confidence interval [66.7%, 99.9%] in Pfizer’s document submitted to the
FDA. In general, the Bayesian confidence interval is narrower than the classical one. Additionally,
our simplified treatment did not take the minor difference in surveillance time into account.

https://scholarcommons.usf.edu/numeracy/vol14/iss2/art7
DOI: https://doi.org/10.5038/1936-4660.14.2.1390

12

Wang: Confidence Intervals of COVID-19 Vaccine Efficacy Rates

> (theta <- qbeta(c(0.025, 0.975), 7/10+1, 1+19))
[1] 0.007646717 0.219527315
> (VE <- (1-2*theta)/(1-theta))
[1] 0.9922944 0.7187252
> curve(dbeta(x, 7/10+1, 1+19))
> curve(dbeta(x, 7/10, 1), lty = 4, add = TRUE)
> curve(dbeta(x, 2, 20), lty = 2,add = TRUE)

#posterior
#prior
#likelihood

The R output of the graph is shown in Figure 5. We again point out that the
likelihood, in this case 𝑃(𝑦|𝜃) = 𝐶120 𝜃1 (1 − 𝜃)19 , is not a probability density
function. This function is proportional to the pdf of Beta(2, 20), and we use it to
show the relative magnitude of the likelihood.

Figure 5. In the R graphic output, the dot-dashed curve is the prior, dashed curve is proportional to
the likelihood, and the solid curve is the posterior.

Table 2 summarizes the confidence intervals of the data in Table 1 using the
minimally informative prior Beta(7/10, 1). They are in good agreement with the
published ones, which were based on classical or nonparametric methods (except
for the group Pfizer all). Although the values are similar, the Bayesian and classical
interpretations of confidence intervals are very different. See above for a Bayesian
interpretation, and the Appendix for the classical interpretation.
Table 2
Comparison of VE Confidence Intervals %
Pfizer all
Pfizer age ≥ 65 years
Moderna all
AstraZeneca I
AstraZeneca II
AstraZeneca combined

Based on this work
[90.3, 97.6]
[71.9, 99.2]
[89.4, 96.8]
[70.7, 97.0]
[41.5, 75.8]
[55.8, 80.4]

Published values
[90.3, 97.6]
[66.7, 99.9]
[89.3, 96.8]
[67.4, 97.0]
[40.0, 76.5]
[54.8, 80.6]

As mentioned in the Introduction, AstraZeneca-Oxford reported a vaccine
efficacy rate of 90.0% for volunteers who received a lower amount then the full
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amount in the second dose, and 62.1% for volunteers who received two full doses.
The company combined the data, and claimed an overall 70.4% efficacy rate. Our
calculated confidence interval for the combined data is narrower than the
confidence intervals of individual trials, as we would expect it.
Although the AstraZeneca-Oxford vaccine’s efficacy rate is less impressive
than that of Pfizer and Moderna, it can still make a significant impact on public
health. Imagine two otherwise identical communities, but one is vaccinated and the
other not. Even if the efficacy rate is only 70%, for every 100 people who become
infected by COVID-19 in the unvaccinated community, there will be on average 30
sick people in the vaccinated community. Furthermore, the Bayesian model gives
the probability of every possible vaccine rate, and public health professionals may
use decision theory to allocate medical resources.

Concluding Remarks
Under the Bayesian framework, one estimates a parameter based on the observed
data and obtains a posterior probability density function for the parameter. This
distribution allows one to talk about the probability of the parameter, which is often
more natural when communicating uncertainty. Specifically, we can state that there
is a 95% probability that Pfizer’s vaccine efficacy rate is between 90.3% and
97.6%, based on the clinical trial data. We have presented a simplified method to
analyze vaccine data based on Bayesian statistics. The posterior probability
distribution in a beta-binomial model is an elementary polynomial or power
function that students with basic algebra skills are familiar with. The explicit
expression for the probability of the unknown parameter can be graphed, and
students can use it to communicate confidence intervals more flexibly. With the
minimally informative prior, we found that the Bayesian confidence intervals are
similar to classical ones reported in medical literature. One can recast a classical
confidence interval into a Bayesian one using our method, and speak about the
probability of vaccine efficacy rates like what the Pfizer scientist did during the
FDA meeting.
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Appendix
In Pfizer’s briefing document submitted to the FDA for the December 10, 2020
meeting, two methods are mentioned in the footnotes, the beta-binomial model and
the Clopper and Pearson method. Among 170 volunteers who became infected by
COVID-19, 8 were from the vaccine group, and 162 from the placebo group. Below
is the R code that reproduces Pfizer’s reported Clopper-Pearson confidence interval
for 𝜃, [0.0205, 0.0906]. Then we use 𝜃 to compute the confidence interval for VE,
[90.0%, 97.9%].
> testall <- binom.test(8, 8+162)
> (theta <- testall$conf.int)
[1] 0.02053273 0.09061668
attr(,"conf.level")
[1] 0.95
> (VE <- (1-2*theta)/(1-theta))
[1] 0.9790368 0.9003537

The Clopper-Pearson interval is commonly referred to as the “exact confidence
interval.” Let us decipher the meaning of R’s output. For the binomial distribution,
the probability mass function is
𝑝(𝑦|𝜃) = 𝐶𝑦𝑛 𝜃 𝑦 (1 − 𝜃)𝑛−𝑦
(see the main text). Let the 95% confidence interval of 𝜃 be [𝐿, 𝑈]. To find U for
the observation 𝑦 = 8 out of 𝑛 = 170, we need to solve the following equation for
𝜃. See Figure A.1.
8

∑ 𝐶𝑘170 𝜃 𝑘 (1 − 𝜃)170−𝑘 = 0.025.
𝑘=0

There are algorithms to solve this equation, and below we use R to verify that when
𝜃 = 0.0906 the above equation is satisfied.
> plot(0:30, dbinom(0:30, 170, 0.09061668), type = "h")
> sum(dbinom(0:8, 170, 0.09061668))
[1] 0.025
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Figure A.1. Classical solutions for the construction of the 95% confidence interval.

Similarly, to find L we solve the following equation:
170

∑ 𝐶𝑘170 𝜃 𝑘 (1 − 𝜃)170−𝑘 = 0.025.
𝑘=8

Below we verify that when 𝜃 = 0.0205, the equation is satisfied.
plot(0:30, dbinom(0:30, 170, 0.02053273), type = "h")
> sum(dbinom(8:170, 170, 0.02053273))
[1] 0.02500001

If we repeat the clinical trial, we may get a different y, which corresponds to a
different confidence interval. The classical construction guarantees that in the limit
of many repeated trials, 95% of the confidence intervals contain the unknown true
value 𝜃. The classical confidence interval reflects the relative frequency with which
the statement “𝜃 is in the interval [𝐿, 𝑈]” is a true statement (Cousins 1995). Robert
D. Cousins claimed that many people do not think about the classical confidence
intervals this way, and wrote a paper titled “Why Isn’t Every Physicist a Bayesian?”
(Cousin 1995), in the spirit of Brad Efron’s article “Why Isn’t Everyone a
Bayesian?” (Efron 1986), to demonstrate the flexibility of the Bayesian method.
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